07:00 , Sep 3, 2007 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
07:00 , Aug 6, 2007 |  BioCentury  |  Finance

Ebb & Flow

With all the big names accounted for in the 2Q07 earnings season, the Street has rendered its verdict on the prospects going forward, punishing big pharma while giving big biotech at least the benefit of...
07:00 , Aug 6, 2007 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
07:00 , Aug 6, 2007 |  BC Week In Review  |  Company News

Anadys, LG Life deal

ANDS restructured and announced it will return to LG rights to ANA380, a nucleotide analog viral polymerase inhibitor in Phase II testing to treat HBV. ANDS said it believes the HCV market is larger than...
01:11 , Aug 2, 2007 |  BC Extra  |  Company News

Anadys returns ANA380 rights, restructures

ANDS announced plans to restructure and discontinue development of ANA380, a nucleotide analog viral polymerase inhibitor in Phase II testing to treat HBV. The announcement follows last Friday's news that ANDS and partner Novartis (NVS;...
07:00 , May 7, 2007 |  BioCentury  |  Finance

Analyst picks & changes

Analyst picks & changes...
08:00 , Jan 8, 2007 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
07:00 , Aug 14, 2006 |  BC Week In Review  |  Company News

Anadys, Novartis deal

ANDS said NVS's exclusive option to license ANA380 has expired and that it will not extend the exclusivity period (see BioCentury, June 6, 2005). However, the company said it is in discussions with NVS for...
07:00 , Jul 3, 2006 |  BioCentury  |  Finance

Anadys chronicles

Anadys chronicles...
07:00 , Jun 12, 2006 |  BioCentury  |  Strategy

Infectious space at Novartis

Infectious space at Novartis...